182 related articles for article (PubMed ID: 18076766)
1. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma.
Lenzi R; Edwards R; June C; Seiden MV; Garcia ME; Rosenblum M; Freedman RS
J Transl Med; 2007 Dec; 5():66. PubMed ID: 18076766
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.
Alvarez RD; Sill MW; Davidson SA; Muller CY; Bender DP; DeBernardo RL; Behbakht K; Huh WK
Gynecol Oncol; 2014 Jun; 133(3):433-8. PubMed ID: 24708919
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
[TBL] [Abstract][Full Text] [Related]
7. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
[TBL] [Abstract][Full Text] [Related]
8. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
Steis RG; Urba WJ; VanderMolen LA; Bookman MA; Smith JW; Clark JW; Miller RL; Crum ED; Beckner SK; McKnight JE
J Clin Oncol; 1990 Oct; 8(10):1618-29. PubMed ID: 2213099
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.
Chapman PB; Kolitz JE; Hakes TB; Gabrilove JL; Welte K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Mertelsmann R
Invest New Drugs; 1988 Sep; 6(3):179-88. PubMed ID: 3263958
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.
Taylor SE; Petschauer JS; Donovan H; Schorzman A; Razo J; Zamboni WC; Edwards RP; Zorn KK
Int J Gynecol Cancer; 2019 Jan; 29(1):147-152. PubMed ID: 30640697
[TBL] [Abstract][Full Text] [Related]
12. Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma.
Freedman RS; Gibbons JA; Giedlin M; Kudelka AP; Kavanagh JJ; Edwards CL; Carrasco CH; Nash MA; Platsoucas CD
J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):443-51. PubMed ID: 9041464
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in peritoneal fluid of ovarian neoplasms.
de Lima CA; Silva Rodrigues IS; Martins-Filho A; Côbo Micheli D; Martins Tavares-Murta B; Candido Murta EF; Simões Nomelini R
J Obstet Gynaecol; 2020 Apr; 40(3):401-405. PubMed ID: 31476946
[TBL] [Abstract][Full Text] [Related]
16. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M
J Clin Oncol; 1995 Dec; 13(12):2961-7. PubMed ID: 8523061
[TBL] [Abstract][Full Text] [Related]
17. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
18. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.
Guastalla JP; Lhomme C; Kerbrat P; Mayer F; Namer M; Goupil P; Charrot P; Heron JF; Chazard M; Richard I
Ann Oncol; 1994 Feb; 5(2):127-32. PubMed ID: 8186155
[TBL] [Abstract][Full Text] [Related]
20. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
